Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Wuhu Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5182-9850; OpenAlex author ID A5085251418. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2019: 3 papers · 2020: 3 papers · 2021: 2 papers · 2022: 2 papers

Papers 10

  1. Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer. First author DOI 10.1002/jcla.24517↗
  2. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
  3. Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33410↗
  4. Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. Co-author DOI 10.3390/cancers13153678↗
  5. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Co-author DOI 10.1016/j.csbj.2020.11.018↗
  6. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. Co-author DOI 10.1038/s41388-020-01407-8↗
  7. Precise and efficient silencing of mutant Kras G12D by CRISPR-CasRx controls pancreatic cancer progression. Co-author DOI 10.7150/thno.46642↗
  8. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Co-author DOI 10.1002/cam4.1957↗
  9. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2430↗
  10. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.2147/cmar.s197911↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 10 shared papers, 2019–2022 · strength 1.05
  2. Tianjiao Li · 9 shared papers, 2019–2022 · strength 0.95
  3. Heli Gao · 9 shared papers, 2019–2022 · strength 0.94
  4. Huaxiang Xu · 9 shared papers, 2019–2022 · strength 0.94
  5. Wenquan Wang · 9 shared papers, 2019–2022 · strength 0.94
  6. Liang Liu · 6 shared papers, 2019–2022 · strength 0.61
  7. Shuo Li · 6 shared papers, 2019–2021 · strength 0.56
  8. Chuntao Wu · 6 shared papers, 2019–2021 · strength 0.56
  9. Xuan Han · 5 shared papers, 2020–2022 · strength 0.55
  10. Liang Liu · 4 shared papers, 2020–2022 · strength 0.45
  11. Hao Li · 4 shared papers, 2019–2021 · strength 0.40
  12. Wang Jiang · 3 shared papers, 2020–2021 · strength 0.33
  13. Xuan Lin · 3 shared papers, 2020–2022 · strength 0.33
  14. Long‐Yun Ye · 3 shared papers, 2020–2022 · strength 0.33
  15. Xu Wang · 2 shared papers, 2021–2022 · strength 0.25
  16. Zhenyu Liao · 2 shared papers, 2021–2022 · strength 0.23
  17. Quanxing Ni · 2 shared papers, 2019 · strength 0.16
  18. Shirong Zhang · 2 shared papers, 2019 · strength 0.16
  19. Zhiwen Xiao · 1 shared paper, 2022 · strength 0.13
  20. Weiding Wu · 1 shared paper, 2022 · strength 0.13
  21. Kaizhou Jin · 1 shared paper, 2022 · strength 0.13
  22. Jia Dong · 1 shared paper, 2021 · strength 0.10
  23. Jiang Long · 1 shared paper, 2020 · strength 0.09
  24. Wei Jin · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.